» Articles » PMID: 23580427

Vaccinia Virus Protein K7 is a Virulence Factor That Alters the Acute Immune Response to Infection

Overview
Journal J Gen Virol
Specialty Microbiology
Date 2013 Apr 13
PMID 23580427
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccinia virus (VACV) encodes many proteins that antagonize the innate immune system including a family of intracellular proteins with a B-cell lymphoma (Bcl)-2-like structure. One of these Bcl-2 proteins called K7 binds Toll-like receptor-adaptor proteins and the DEAD-box RNA helicase DDX3 and thereby inhibits the activation of NF-κB and interferon regulatory factor 3. However, the contribution of K7 to virus virulence is not known. Here a VACV lacking the K7R gene (vΔK7) was constructed and compared with control viruses that included a plaque purified wt (vK7), a revertant with the K7R gene reinserted (vK7-rev) and a frame-shifted virus in which the translational initiation codon was mutated to prevent K7 protein expression (vK7-fs). Data presented show that loss of K7 does not affect virus replication in cell culture or in vivo; however, viruses lacking the K7 protein were less virulent than controls in murine intradermal (i.d.) and intranasal (i.n.) infection models and there was an altered acute immune response to infection. In the i.d. model, vΔK7 induced smaller lesions than controls, and after i.n. infection vΔK7 induced a reduced weight loss and signs of illness, and more rapid clearance of virus from infected tissue. Concomitantly, the intrapulmonary innate immune response to infection with vΔK7 showed increased infiltration of NK cells and CD8⁺ T-cells, enhanced MHC class II expression by macrophages, and enhanced cytolysis of target cells by NK cells and VACV-specific CD8⁺ T-cells. Thus protein K7 is a virulence factor that affects the acute immune response to infection.

Citing Articles

An Attenuated and Highly Immunogenic Variant of the Vaccinia Virus.

Shchelkunov S, Yakubitskiy S, Titova K, Pyankov S, Shulgina I, Starostina E Acta Naturae. 2024; 16(2):82-89.

PMID: 39188266 PMC: 11345087. DOI: 10.32607/actanaturae.27384.


A comprehensive review of monkeypox virus and mpox characteristics.

Alakunle E, Kolawole D, Diaz-Canova D, Alele F, Adegboye O, Moens U Front Cell Infect Microbiol. 2024; 14:1360586.

PMID: 38510963 PMC: 10952103. DOI: 10.3389/fcimb.2024.1360586.


HDAC5 enhances IRF3 activation and is targeted for degradation by protein C6 from orthopoxviruses including Monkeypox virus and Variola virus.

Lu Y, Zhao Y, Gao C, Suresh S, Men J, Sawyers A Cell Rep. 2024; 43(3):113788.

PMID: 38461415 PMC: 11650635. DOI: 10.1016/j.celrep.2024.113788.


Oncolytic vaccinia virus and cancer immunotherapy.

Xu L, Sun H, Lemoine N, Xuan Y, Wang P Front Immunol. 2024; 14:1324744.

PMID: 38283361 PMC: 10811104. DOI: 10.3389/fimmu.2023.1324744.


The Viral Protein K7 Inhibits Biochemical Activities and Condensate Formation by the DEAD-box Helicase DDX3X.

Venus S, Tandjigora K, Jankowsky E J Mol Biol. 2023; 435(19):168217.

PMID: 37517790 PMC: 10528715. DOI: 10.1016/j.jmb.2023.168217.


References
1.
Staib C, Kisling S, Erfle V, Sutter G . Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J Gen Virol. 2005; 86(Pt 7):1997-2006. DOI: 10.1099/vir.0.80646-0. View

2.
Parker A, Parker S, Yokoyama W, Corbett J, Buller R . Induction of natural killer cell responses by ectromelia virus controls infection. J Virol. 2007; 81(8):4070-9. PMC: 1866162. DOI: 10.1128/JVI.02061-06. View

3.
Sutter G, Staib C . Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord. 2003; 3(3):263-71. DOI: 10.2174/1568005033481123. View

4.
Sumner R, Ren H, Smith G . Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy. J Gen Virol. 2013; 94(Pt 5):1121-1126. PMC: 3709586. DOI: 10.1099/vir.0.049700-0. View

5.
Harte M, Haga I, Maloney G, Gray P, Reading P, Bartlett N . The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med. 2003; 197(3):343-51. PMC: 2193841. DOI: 10.1084/jem.20021652. View